Attovia extends biotech IPO streak with $289M listing for three I&I drugs
For the first time since the winter of 2025, the biotech industry is celebrating three consecutive weeks of initial public offerings. Attovia Therapeutics, an immunology and inflammation (I&I) biotech, extended the drug development industry's sizzling ...
We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.
Also reported by 1 other outlet
- Attovia adds to biotech IPO momentum with $289M offering biopharmadive.com
